Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2009

Meyerhardt JA, Ogino S, Kirkner GJ, Chan AT, Wolpin B, Ng K, et al. Interaction of molecular markers and physical activity on mortality in patients with colon cancer. Clin Cancer Res. 2009;15(18):5931-6.

Peng H-, Halsey K, Sun C-, Manucha V, Nugent S, Rodgers WH, et al. Clinical utility of postchemoradiation endoscopic brush cytology and biopsy in predicting residual esophageal adenocarcinoma. Cancer. 2009;117(6):463-72.

Gordon JK, Magro C, Lu T, Schneider R, Chiu A, Furman RR, et al. Overlap between systemic lupus erythematosus and Kikuchi Fujimoto disease: a clinical pathology conference held by the Department of Rheumatology at Hospital for Special Surgery. HSS J. 2009;5(2):169-77.

Trakala M, Arias CF, García MI, M Moreno-Ortiz C, Tsilingiri K, Fernández PJ, et al. Regulation of macrophage activation and septic shock susceptibility via p21(WAF1/CIP1). Eur J Immunol. 2009;39(3):810-9.

Wadlow RC, Wittner BS, S Finley A, Bergquist H, Upadhyay R, Finn S, et al. Systems-level modeling of cancer-fibroblast interaction. PLoS One. 2009;4(9):e6888.

Glezerman I, Kris MG, Miller V, Seshan S, Flombaum CD. Gemcitabine nephrotoxicity and hemolytic uremic syndrome: report of 29 cases from a single institution. Clin Nephrol. 2009;71(2):130-9.

Carbone A, Cesarman E, Spina M, Gloghini A, Schulz TF. HIV-associated lymphomas and gamma-herpesviruses. Blood. 2009;113(6):1213-24.

Yemelyanova A, Vang R, Seidman JD, Gravitt PE, Ronnett BM. Endocervical adenocarcinomas with prominent endometrial or endomyometrial involvement simulating primary endometrial carcinomas: utility of HPV DNA detection and immunohistochemical expression of p16 and hormone receptors to confirm the cervical origin of. Am J Surg Pathol. 2009;33(6):914-24.

Locke JE, Magro CM, Singer AL, Segev DL, Haas M, Hillel AT, et al. The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection. Am J Transplant. 2009;9(1):231-5.

2008

Niesvizky R, Jayabalan DS, Christos PJ, Furst JR, Naib T, Ely S, et al. BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma. Blood. 2008;111(3):1101-9.